Mounjaro® Subcutaneous Injection 2.5mg ATEOS®

Mounjaro® (tirzepatide) is a once-weekly subcutaneous injection developed by Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation for the treatment of type 2 diabetes.

It is the world’s first dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, designed to improve blood glucose control by enhancing insulin secretion and improving insulin sensitivity.

The medication is administered using a single-use autoinjector device (ATEOS®), which simplifies the injection process for patients.

The typical dosing regimen starts with 2.5 mg once weekly for the first 4 weeks, followed by an increase to the maintenance dose of 5 mg once weekly.

If additional glycemic control is needed, the dose can be increased by 2.5 mg increments at intervals of at least 4 weeks, up to a maximum of 15 mg once weekly.